Processa Pharmaceuticals Announces Prioritization on Development of Next Generation Chemotherapies
February 21, 2023 08:30 ET | Processa Pharmaceuticals, Inc.
Our Next Generation Chemotherapies (NGCs) are cancer treatments where the metabolism and/or distribution of an FDA-approved drug has been altered to provide potentially safer and more effective...
Straits Research Pvt Ltd
Oncology Biosimilar Market Size is projected to reach USD 15.62 billion by 2031, growing at a CAGR of 20.5%: Straits Research
November 23, 2022 10:25 ET | Straits Research
New York, United States, Nov. 23, 2022 (GLOBE NEWSWIRE) -- A biosimilar is a generic version of a well-known biologic drug. Biologic drugs are medicines made from living things like cells, tissues,...
BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal
June 24, 2022 09:00 ET | BriaCell Therapeutics Corp.
Anti-Cancer activity of BriaCell’s lead candidate, Bria-IMT™, in advanced breast cancer patients was published in a leading peer-reviewed publication. Bria-IMT™, through a novel mechanism of action,...
Allarity Therapeutics Provides Update on Dovitinib Program
March 15, 2022 08:32 ET | Allarity Therapeutics, Inc.
FOR IMMEDIATE RELEASE Allarity has requested a Type C meeting with the FDA to discuss potential clinical paths to support approval of dovitinib in view of the regulatory agency’s recent Refusal to...
Celsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors
June 08, 2021 08:00 ET | Celsion CORP
25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez, MD LAWRENCEVILLE, N.J., June 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation...
Allarity Therapeutics Submits Premarket Approval Application to U.S. FDA for DRP® Companion Diagnostic for Dovitinib
April 02, 2021 07:00 ET | Allarity Therapeutics A/S
- Submission precedes expected NDA filing for dovitinib in 2021 - Premarket Approval will allow U.S. marketing of DRP-Dovitinib as companion diagnostic to dovitinib Press release ...
Allarity Therapeutics Initiates Phase 2 Trial of IXEMPRA® in Europe for the Treatment of Metastatic Breast Cancer
March 04, 2021 09:00 ET | Allarity Therapeutics A/S
Press release       Hørsholm, Denmark (4 March 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced that it has enrolled the first patient in its European Phase 2...
Celsion Receives $2 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
February 23, 2021 08:00 ET | Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years LAWRENCEVILLE, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a...
Celsion Corporation Announces Formation of Vaccine Advisory Board
February 12, 2021 08:30 ET | Celsion CORP
Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2 LAWRENCEVILLE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) --...
Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years
January 27, 2021 20:30 ET | DelveInsight Business Research LLP
Los Angeles, USA, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Non-Muscle Invasive Bladder Cancer Pipeline Analysis Shows Tremendous Growth Opportunities for the Coming Years With over 30+ players proactively...